Enrolling and retaining high risk women in HIV prevention/vaccine trials.
1. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Probe Study With an Additional Open-Label Control Arm to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 gag Vaccine in Subjects With Chronic Hepatitis C (Merck 022)
Principal Investigator: Melissa M. Gaitanis, MD
3/04- : $86,058
2. A Phase I Dose Ranging Study of the Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Trigene and the MRKAd6 HIV-1 Trigene Vaccines Alone and in Combination in Healthy Adults (Merck V526-001)
Principal Investigator: Melissa M. Gaitanis, MD
4/05- : $90,360
3. A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNETM) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects with CD4 counts ³200 500/µl (Bavarian Nordic, POX-MVA-011)
Principal Investigator: Melissa M. Gaitanis, MD
Start Date (Projected): 6/06
